ADX 68692
Alternative Names: ADX-68692Latest Information Update: 02 Sep 2024
Price :
$50 *
At a glance
- Originator Addex Therapeutics
- Class Small molecules
- Mechanism of Action Follicle stimulating hormone modulators; FSH receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Endometriosis
Most Recent Events
- 20 Aug 2024 Discontinued - Preclinical for Benign prostatic hyperplasia in Switzerland (unspecified route) (Addex Therapeutics pipeline August 2024)
- 20 Aug 2024 Discontinued - Preclinical for Endometriosis in Switzerland (unspecified route) (Addex Therapeutics pipeline, August 2024)
- 15 Sep 2010 Preclinical trials in Benign prostatic hyperplasia in Switzerland (unspecified route) prior to September 2010